Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) EBT Margin (2017 - 2025)

VYNE Therapeutics' EBT Margin history spans 9 years, with the latest figure at 5747.0% for Q2 2025.

  • For Q2 2025, EBT Margin fell 104950.0% year-over-year to 5747.0%; the TTM value through Jun 2025 reached 7642.26%, down 176484.0%, while the annual FY2025 figure was 4689.82%, 327078.0% up from the prior year.
  • EBT Margin reached 5747.0% in Q2 2025 per VYNE's latest filing, down from 4301.5% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 3230.77% in Q4 2021 to a low of 26717.24% in Q4 2022.
  • Average EBT Margin over 5 years is 7857.86%, with a median of 5909.0% recorded in 2023.
  • Peak YoY movement for EBT Margin: plummeted -2348647bps in 2022, then soared 1862250bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 3230.77% in 2021, then plummeted by -727bps to 26717.24% in 2022, then surged by 70bps to 8094.74% in 2023, then crashed by -79bps to 14469.88% in 2024, then soared by 60bps to 5747.0% in 2025.
  • Per Business Quant, the three most recent readings for VYNE's EBT Margin are 5747.0% (Q2 2025), 4301.5% (Q1 2025), and 14469.88% (Q4 2024).